TVTX Travere Therapeutics, Inc.
$66.17▼ -1.98%
Healthcare
Other
After hours
$66.17▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.15M
Avg Volume (10D) 1.21M
Key Metrics & Fundamentals
Market Cap
$6.24B
P/E Ratio
–
Div Yield
–%
52W Range
22.06 - 68.73
% vs 50 MA
8.51%
% vs 200 MA
53.73%
RSI-14
57.2
MACD Histogram
-0.3000
Beta (1Y vs SPY)
1.46
Free Cash Flow
$37.00M
Gross Rev
$169.58M
Gross Profit
$160.35M
EBITDA
-$28.63M
COGS
$9.24M
Operating Exp
$156.40M
Operating Income
$3.95M
EBIT
$3.95M
Pretax Income
-$35.00M
Net Income
-$34.80M
EPS (Diluted)
-0.37
Price & Volume History
Loading chart…
Recent News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Sep 11, 2026 9:00 PM
Travere Therapeutics' Outlook Brightens As Turnaround Looms
Investor's Business Daily · Sep 8, 2026 7:44 PM
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
Insider Monkey · Sep 4, 2026 10:44 AM
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Investor's Business Daily · Aug 24, 2026 4:56 PM
IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'
Investor's Business Daily · Aug 21, 2026 5:09 PM
Three Biotech Stocks Stick Out With Their Stellar Charts
Investor's Business Daily · Aug 21, 2026 4:09 PM
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
MarketBeat · Aug 18, 2026 10:01 AM
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 12:13 AM
Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss
Simply Wall St. · Aug 7, 2026 7:11 AM
Travere Therapeutics (TVTX) On Q2 Results And FILSPARI Hopes As Fair Value Stays In View
Simply Wall St. · Aug 7, 2026 4:29 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See TVTX's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.